Skip to main content

Table 5 Effect of NOMAC on osteodensitometry (DEXA) measurements of L1 to L5 of the lumbar rachis

From: Preclinical pharmacological profile of nomegestrol acetate, a synthetic 19-nor-progesterone derivative

Treatment

DEXA measurements (%)

Day 20

Day 41

Day 62

Day 90

Intact control†

104.8 ± 1.4

105.5 ± 2.5

105.9 ± 1.5

108.0 ± 1.4

% treatment of intact control

100

100

100

100

OVX control†

94.4 ± 2.3

95.5 ± 1.7

97.0 ± 2.8

95.1 ± 2.7

% treatment of intact control

−9.9

−9.4

−8.4

−12

E2 (1 μg/kg/day)†

98.2 ± 0.7

100.8 ± 1.4

103.6 ± 1.7

102.8 ± 1.8

% treatment of OVX control

+4.0

+5.5

+6.8*

+8.1**

NOMAC (1 mg/kg/day)†

92.7 ± 0.8

93.4 ± 0.5

92.2 ± 1.1

93.2 ± 2.3

% treatment of OVX control

−1.8

−2.3

−4.9

−2.0

E2 (1 μg/kg/day) + NOMAC (1 mg/kg/day)†

98.7 ± 1.1

97.5 ± 1.9

102.0 ± 1.0

101.5 ± 1.1

% treatment of OVX control

+4.6*

+2.1

+5.2*

+6.7*

  1. ANOVA, analysis of variance; DEXA, dual-energy X-ray absorptiometry; E2, 17β-estradiol; NOMAC, nomegestrol acetate; OVX, ovariectomized. † Data are percentages of DEXA values and are expressed as the mean ± standard error of the mean. * P<0.05; ** P<0.01 compared with OVX control animals (ANOVA).
  2. At 3-week intervals, osteodensitometry measurements of the lumbar vertebrae (L1 to L6) were made using DEXA. After 90 days, the animals were sacrificed, the femur and L5 vertebra removed, and dynamic osteodensitometric measurements were made.